Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly Non-Current Deffered Revenue of $5.8 million in Q4 2025, down 4.91% quarter-over-quarter from $6.1 million in Q3 2025, and up 202.41% on a YoY basis from $1.9 million in Q4 2024.
Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $5.8 million for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue rose 202.41% year-over-year to $5.8 million; the TTM figure through Dec 2025 stood at $5.8 million (up 202.41% YoY), while the FY2025 annual figure was $5.8 million, up 202.41% from the prior year.
- Non-Current Deffered Revenue was $5.8 million for Q4 2025 at Dianthus Therapeutics, down from $6.1 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $6.4 million in Q2 2021 to a low of $640000.0 in Q3 2024.
- Historically, Non-Current Deffered Revenue has averaged $3.2 million across 5 years, with a median of $1.9 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue tumbled 87.64% in 2022, then jumped 848.12% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $6.4 million in 2021, then sank by 87.64% to $791000.0 in 2022, then retreated by 6.95% to $736000.0 in 2023, then jumped by 159.24% to $1.9 million in 2024, then surged by 202.41% to $5.8 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $5.8 million (Q4 2025), $6.1 million (Q3 2025), and $1.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | 5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 6.07 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 640,000.00 |
| Jun 30, 2024 | 682,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Dec 31, 2023 | 736,000.00 |
| Sep 30, 2023 | 745,000.00 |
| Dec 31, 2022 | 791,000.00 |
| Dec 31, 2021 | 6.40 Mn |
| Sep 30, 2021 | 6.40 Mn |
| Jun 30, 2021 | 6.40 Mn |
| Mar 31, 2021 | 6.36 Mn |
| Dec 31, 2020 | 6.30 Mn |
| Sep 30, 2020 | 6.21 Mn |
| Jun 30, 2020 | 6.44 Mn |
| Mar 31, 2020 | 6.34 Mn |
| Dec 31, 2019 | 6.21 Mn |